BlackRock, Inc. Reduces Stake in MBX Biosciences Inc to 4.8%

BlackRock, Inc. has filed a Schedule 13G/A with the SEC, dated April 27, 2026, regarding its holdings in MBX Biosciences Inc (MBX). As of the event date on March 31, 2026, BlackRock reported beneficial ownership of 2,287,497 shares of common stock, representing a 4.8% ownership stake in the company. This filing serves as an amendment (Amendment No. 1) to a previous statement. Notably, the reporting indicates that BlackRock's ownership has fallen below the 5% threshold, as the firm now holds sole dispositive power over 2,287,497 shares and sole voting power over 2,246,477 shares. The filing specifies that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiary entities under BlackRock, Inc. are involved in the beneficial ownership, though no single person's interest exceeds five percent of the total outstanding common shares. The filing was signed by Spencer Fleming, Managing Director.